ADC Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de ADC Therapeutics han disminuido a una tasa media anual de -8.4%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 67.4% al año.

Información clave

-8.4%

Tasa de crecimiento de los beneficios

14.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	67.4%
Rentabilidad financiera	n/a
Margen neto	-345.1%
Próxima actualización de resultados	06 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

Aug 09

Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts

Jul 21

Sobi to pay ADC Therapeutics $55M upfront to license Zynlonta in Europe, other regions

Jul 08

ADC Therapeutics begins dosing in study of Zynlonta combo for blood cancer subtype

Jun 29

Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?

Jun 22

ADC Therapeutics SA (NYSE:ADCT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 06

Growth Investors: Industry Analysts Just Upgraded Their ADC Therapeutics SA (NYSE:ADCT) Revenue Forecasts By 21%

Mar 05

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero ADC Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:ADCT Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	70	-240	106	4
30 Sep 23	123	-179	111	17
30 Jun 23	184	-181	124	17
31 Mar 23	182	-199	134	17
31 Dec 22	210	-157	143	17
30 Sep 22	157	-166	146	17
30 Jun 22	94	-187	143	17
31 Mar 22	80	-195	142	17
31 Dec 21	34	-230	136	17
30 Sep 21	17	-252	129	0
30 Jun 21	4	-200	116	0
31 Mar 21	0	-254	100	0
31 Dec 20	0	-246	77	0
30 Sep 20	0	-226	53	0
30 Jun 20	0	-237	35	0
31 Mar 20	1	-135	19	0
31 Dec 19	2	-116	14	0
30 Sep 19	3	-112	11	0
30 Jun 19	3	-111	11	0
31 Mar 19	2	-117	10	0
31 Dec 18	1	-123	9	0
31 Dec 17	2	-90	8	0

Ingresos de calidad: ADCT actualmente no es rentable.

Margen de beneficios creciente: ADCT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ADCT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 8.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ADCT en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ADCT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: El pasivo de ADCT supera su activo, por lo que es difícil calcular su rentabilidad financiera.

ADC Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ADC Therapeutics SA to Report Q2, 2023 Results on Aug 08, 2023

Recent updates

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

New major risk - Share price stability

Consensus revenue estimates fall by 11%

ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

ADC Therapeutics: Slowly Moving Toward Solvency

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 20%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ADC Therapeutics SA to Report Q2, 2023 Results on Aug 08, 2023

China National Medical Products Administration Accepts Biologics License Application and Grants Priority Review for ZYNLONTA for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA Announces Voluntary Pause in the Enrollment of New Patients in the Phase 2 LOTIS-9 Clinical Trial Evaluating ZYNLONTA

Now 31% undervalued after recent price drop

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

High number of new directors

Price target decreased by 18% to US$9.33

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(R) in Relapsed/Refractory DLBCL

ADC Therapeutics: Maybe A 2024 Story

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target increased by 9.4% to US$12.40

Consensus revenue estimates decrease by 29%, EPS upgraded

ADC Therapeutics SA Announces Updated Results from LOTIS-2 Trial to Be Presented at the European Hematology Association 2023 Hybrid Congress

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

Price target increased by 8.5% to US$13.20

Price target increased by 7.4% to US$13.20

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Consensus revenue estimates fall by 16%

Price target decreased by 15% to US$11.14

Price target decreased by 8.5% to US$12.29

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $60 million.

ADC Therapeutics stock slips after pricing stock offering by seller

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

ADC Therapeutics Sa Appoints Jose Carmona as Chief Financial Officer

Jose Carmona joins ADC Therapeutics as CFO

Price target decreased to US$14.17

High number of new directors

Price target decreased to US$14.83

Price target increased to US$19.20

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA Announces Abstracts to Be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology

Price target decreased to US$17.67

Consensus revenue estimates increase by 13%

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Price target decreased to US$21.20

ADC Therapeutics SA announced that it expects to receive $181.249999 million in funding from Owl Rock Opportunistic GP, LLC, OR Opportunistic DL (C) GP, LLC,

Consensus forecasts updated

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

High number of new directors

ADC Therapeutics SA Doses First Patient in Phase 1B Clinical Trial of ADCT-601

Desglose de ingresos y gastos
Beta